Literature DB >> 23271774

Role of active surveillance in the management of localized prostate cancer.

Allison S Glass1, Matthew R Cooperberg, Maxwell V Meng, Peter R Carroll.   

Abstract

Active surveillance is an increasingly recognized treatment option for men with low-risk prostate cancer. Despite encouraging evidence for oncologic efficacy and reduction in morbidity, several barriers contribute to the underuse of this management strategy. Consistent selection criteria as well as identification and validation of triggers for subsequent intervention are essential. Incorporation of novel biomarkers as well as advanced imaging techniques may improve surveillance strategies by better defining eligibility as well as improving prompt detection of disease progression.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23271774      PMCID： PMC3540869          DOI： 10.1093/jncimonographs/lgs032

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN： 1052-6773


  59 in total

1.  Preoperative nomograms incorporating magnetic resonance imaging and spectroscopy for prediction of insignificant prostate cancer.

Authors:  Amita Shukla-Dave; Hedvig Hricak; Oguz Akin; Changhong Yu; Kristen L Zakian; Kazuma Udo; Peter T Scardino; James Eastham; Michael W Kattan
Journal:  BJU Int       Date:  2011-09-20       Impact factor: 5.588

2.  Active surveillance with selective delayed intervention for favorable risk prostate cancer.

Authors:  Laurence Klotz
Journal:  Urol Oncol       Date:  2006 Jan-Feb       Impact factor: 3.498

3.  Prostate cancer: evaluation with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Authors:  Emanuele Casciani; Elisabetta Polettini; Luca Bertini; Paolo Emiliozzi; Mostafa Amini; Vito Pansadoro; Gian Franco Gualdi
Journal:  Radiol Med       Date:  2004 Nov-Dec       Impact factor: 3.469

4.  Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

Authors:  René Raaijmakers; Wim J Kirkels; Monique J Roobol; Mark F Wildhagen; Fritz H Schrder
Journal:  Urology       Date:  2002-11       Impact factor: 2.649

5.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

6.  20-year outcomes following conservative management of clinically localized prostate cancer.

Authors:  Peter C Albertsen; James A Hanley; Judith Fine
Journal:  JAMA       Date:  2005-05-04       Impact factor: 56.272

7.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer.

Authors:  Patricia A Ganz; John M Barry; Wylie Burke; Nananda F Col; Phaedra S Corso; Everett Dodson; M Elizabeth Hammond; Barry A Kogan; Charles F Lynch; Lee Newcomer; Eric J Seifter; Janet A Tooze; Kasisomayajula Viswanath; Hunter Wessells
Journal:  Ann Intern Med       Date:  2012-02-20       Impact factor: 25.391

8.  Cellular proliferation in prostatic adenocarcinoma as assessed by bromodeoxyuridine uptake and Ki-67 and PCNA expression.

Authors:  M L Cher; K Chew; W Rosenau; P R Carroll
Journal:  Prostate       Date:  1995-02       Impact factor: 4.104

9.  An analysis of men with clinically localized prostate cancer who deferred definitive therapy.

Authors:  Manish I Patel; Dino T DeConcini; Ernesto Lopez-Corona; Makato Ohori; Thomas Wheeler; Peter T Scardino
Journal:  J Urol       Date:  2004-04       Impact factor: 7.450

10.  Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer.

Authors:  P C Albertsen; J A Hanley; D F Gleason; M J Barry
Journal:  JAMA       Date:  1998-09-16       Impact factor: 56.272
View more
  4 in total

1.  Active surveillance for low-risk prostate cancer in Austria: the online registry of the Qualitätspartnerschaft Urologie (QuapU).

Authors:  Klaus Eredics; Karl Dorfinger; Gero Kramer; Anton Ponholzer; Stephan Madersbacher
Journal:  Wien Klin Wochenschr       Date:  2016-12-21       Impact factor: 1.704

2.  Prostate specific antigen velocity risk count predicts biopsy reclassification for men with very low risk prostate cancer.

Authors:  Hiten D Patel; Zhaoyong Feng; Patricia Landis; Bruce J Trock; Jonathan I Epstein; H Ballentine Carter
Journal:  J Urol       Date:  2013-09-20       Impact factor: 7.450

3.  Racial and Ethnic Differences in Prostate Cancer Survivors' Perceived Engagement in Treatment Decision-Making.

Authors:  Nynikka R Palmer; Steven E Gregorich; Jennifer Livaudais-Toman; Jane Jih; Celia P Kaplan
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-07

4.  Evolution of a CDC Public Health Research Agenda for Low-Risk Prostate Cancer.

Authors:  Ingrid J Hall; Judith Lee Smith
Journal:  Am J Prev Med       Date:  2015-12       Impact factor: 5.043
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.